Roche’s audio webcast replay on efficacy and safety of risdiplam in patients with type 2/3 spinal muscular atrophy presented at SMA Europe 2020
Roche has hosted a live audio webcast and conference call on Thursday, 6 February 2020.
Karl Mahler, Head of Investor Relations
- Phase II/III SUNFISH part 2 data - efficacy and safety of risdiplam in patients with type 2 or type 3 SMA
Paulo Fontoura, Global Head Neuroscience and Rare Diseases Clinical Development
Please register to access the webcast replay.